Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma Jeff D. MooreBruce J. DezubeJean-Pierre Sommadossi ORIGINAL ARTICLE Pages: 173 - 179
Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer Sotaro SadahiroShigeru OhkiHiroyasu Makuuchi ORIGINAL ARTICLE Pages: 180 - 184
Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats Sujata VaidyanathanMehdi Boroujerdi ORIGINAL ARTICLE Pages: 185 - 192
Ara-C differentially affects multiprotein forms of human cell DNA polymerase Philip W. WillsRobert HickeyLinda Malkas ORIGINAL ARTICLE Pages: 193 - 203
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan Saad AkhtarRobert A. BeckmanJonathan Wright ORIGINAL ARTICLE Pages: 204 - 210
Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats Akinobu KuritaShoichi KadoTeruo Yokokura ORIGINAL ARTICLE Pages: 211 - 220
Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer Deborah W. KnappNita W. GlickmanLawrence T. Glickman ORIGINAL ARTICLE Pages: 221 - 226
Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer D. OuelletA. P. PericlouR. L. Lalonde ORIGINAL ARTICLE Pages: 227 - 234
Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy Osama M. AshourFardos N. M. NaguibMahmoud H. el Kouni ORIGINAL ARTICLE Pages: 235 - 240
The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line Hiroshi MeseAkira SasakiTomohiro Matsumura ORIGINAL ARTICLE Pages: 241 - 245
Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative William C. RoseFrancis Y. F. LeeJohn Kadow ORIGINAL ARTICLE Pages: 246 - 250
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer Robert PelleyRam GanapathiG. Thomas Budd SHORT COMMUNICATION Pages: 251 - 254